Regarding the efficacy of neoadjuvant PD-1 blockade plus chemotherapy in other oncogene-mutant NSCLCs, patients harbouring the ROS1 fusion, RET fusion, or HER2 insertion were found to be correlated with a better pathological response, while this combined regimen seemed to be less effective in patients with MET-amplified NSCLC [15, 16]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.